Adaptive radiation for early-stage lung cancer or small metastases
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a more precise radiation technique (stereotactic body radiotherapy) for early-stage lung cancer or small lung tumors. It aims to reduce side effects by eliminating the usual safety margin around the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage non-small cell lung cancer that can't be surgically removed, or you have up to 3 small lung metastases (each ≤5 cm).
- You are 18 years or older and in good enough health to get around (performance status 0–2).
- Your blood counts meet minimum levels: hemoglobin ≥80 g/L, platelets ≥100,000/μL, and white blood cells ≥1,500/μL.
- Your kidney and liver function are within safe ranges (creatinine/bilirubin no more than 1.25–1.5 times normal).
- Your lung function is adequate (FEV1 at least 0.5 L).
- You do not have serious heart conditions, active infections, or other reasons that make radiotherapy unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to deliver radiation to brain metastases from non-small cell lung cancer, using MRI scans to guide the treatment and reduce the area exposed. The goal is to see if this approach is safe and effective while possibly lowering side effects.
This trial studies a precise, high-dose radiation technique (SBRT) to treat tumors in the lungs. It may help control cancer in people who either have early-stage lung cancer that is not fully operable or have limited lung metastases from other cancers.
This trial tests a single very high dose of precisely targeted radiation to treat early-stage lung cancer. It aims to destroy the tumor with one treatment session, which may be more convenient and effective than standard radiation.
This trial tests whether a special type of focused radiation therapy can effectively treat advanced non-small cell lung cancer (the most common type) as an upfront treatment. It may help patients avoid or delay chemotherapy while controlling their cancer.
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
Hear when a new Adaptive Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.